Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03221699
Other study ID # H-16045754
Secondary ID
Status Completed
Phase N/A
First received March 30, 2017
Last updated July 14, 2017
Start date February 1, 2017
Est. completion date March 22, 2017

Study information

Verified date July 2017
Source Bispebjerg Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Bothersome odor from the axilla is in most cases caused by Corynebacterium spp. Anti-microbial effects of zinc oxide (ZnO) are well documented.

The overall objective of this study is to verify that repeated applications of a ZnO containing formulation can be directly linked to reduced growth of Corynebacterium spp. in the axillae.


Description:

In the trial the effects of the ZnO formulation on the skin of the forearms and axillae are investigated simultaneously. In both locations the skin is treated daily with the ZnO/placebo formulations.

At day -8 skin areas of the forearms and the axillae are sampled by adhesive tape that is extracted in phosphate-buffered saline (PBS) and PBS extract analyzed on total proteins (BCA) and IL-1α. In the axillae swabs are taken for Corynebacterium spp. semi quantification and pH is measured in the axillae and on the forearm.

At day 0 treated skin areas of the forearms and the axillae are sampled by adhesive tape that is extracted in PBS and PBS extract analyzed on total proteins (BCA) and IL-1α, and compared to adjacent non-treated skin. In the axillae and on the forearms, swabs are first taken for Corynebacterium spp. semi quantification followed by wounding using ablative fractional (10%) carbon dioxide laser at 20 millijoule/microbeam and pediatric lancet. pH is measured in the axillae and on the forearm.

Progress of wound healing is assessed by dermatoscopy at days 3, 4 and 5. At day 5 swabs are taken in the axillae for Corynebacterium spp. semi quantification and pH is measured. Furthermore, skin areas of the axillae are sampled by adhesive tape that is extracted in PBS and PBS extract analyzed on total proteins (BCA) and IL-1α.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date March 22, 2017
Est. primary completion date March 22, 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Healthy males and females

- Age between 18 and 65 years

- Non-smoking

- Written informed consent

Exclusion Criteria:

- No current or past skin disorder

- Immunosuppressive treatment

- Pregnant and breast feeding women

- Hypersensitivity to zinc and/or other ingredients in the products

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Formula with ZnO
Forearms and axillae are treated by the volunteers once daily with a standardized amount of the roll-on with ZnO
Formula without ZnO
Forearms and axillae are treated by the volunteers once daily with a standardized amount of the roll-on without ZnO

Locations

Country Name City State
Denmark Bispebjerg Hospital Copenhagen Copenhagen NV

Sponsors (2)

Lead Sponsor Collaborator
Lars Nannestad Jorgensen Colgate Palmolive

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Growth of Corynebacterium spp. after 8 days of treatment Skin surface swabs are cultured, and Corynebacterium spp. identified by light microscopy/MALDI-TOF mass spectrometry and semiquantified. Day 0
Secondary Wound healing Dermatoscopy is used to assess the erythema, crust formation and healing Day 3, day 4 and day 5
Secondary Quantification of total proteins and interleukin (IL)-1a Corneocytes are sampled on both forearms and axillae by adhesive tape (Sebutape®; CuDerm, Dallas, Texas, USA) for quantification of total proteins (BCA) and IL-1a levels by ELISA. Day -8, day 0 and day 5
Secondary Changes in skin acidity level (pH) pH measurements are performed on both axillae Day -8 and day 5
Secondary Pain McGill pain questionnaire Day -8, day 0, day 3, day 4 and day 5